Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

VALEANT PHARMACEUTICALS INTL INC T.VRX

"Valeant Pharmaceuticals is a global specialty pharmaceutical firm with a focus on branded products for the dermatology, gastrointestinal, and ophthalmology markets. The firm also has a branded generics business that operates primarily in Latin America, Eastern Europe, and Asia."


TSX:VRX - Post by User

Post by Carlos66on Jul 12, 2016 3:03pm
109 Views
Post# 25045550

VRX up marginally...

VRX up marginally...
while others up way more should show you that VRX is in its own dark world.
I doubt very much  if their debt is manageable.

FYI....

Jim Chanos said "everybody" is using metrics that are "just as bad as Valeant's accounting ... I think that a lot of people are operating in this stock on the basis of false presumptions."

He continued:

The whole idea was to buy things and then hike prices dramatically. The payers have woken up — that is the difference here. Valeant was genius at gaming the system; that game is over ... This was financial engineering, this was not pharmaceutical development.
Biography.....James S. Chanos is an American investment manager and currently serves as president and founder of Kynikos Associates ($3-6Bn AUM), a New York City registered investment advisor that is focused on short selling. Revealed the fraud at Enron & Worldcom.


carlos
<< Previous
Bullboard Posts
Next >>